ORIGINAL ARTICLE

The Chest Australia Trial: a randomised controlled trial of an intervention to increase consultation rates in smokers at risk of lung cancer

Jon D Emery,1,2,3 Sonya R Murray,2 Fiona M Walter,1,2,3 Andrew Martin,4 Stephen Goodall,5 Danielle Mazza,6 Emily Habgood,1 Yvonne Kutzer,2,7 David John Barnes,8,9 Peter Murchie10

ABSTRACT

Background International research has focused on screening and mass media campaigns to promote earlier patient presentation and detect lung cancer earlier. This trial tested the effect of a behavioural intervention in people at increased risk of lung cancer on help-seeking for respiratory symptoms.

Methods Parallel, individually randomised controlled trial. Eligible participants were long-term smokers with at least 20 pack-years, aged 55 and above. The CHEST intervention entailed a consultation to discuss and implement a self-help manual, followed by self-monitoring reminders to encourage help-seeking for respiratory symptoms. The control group received a brief discussion about lung health. Both groups had baseline spirometry. Telephone randomisation was conducted, 1:1, stratified Medical Research Council (MRC) dyspnoea score and general practice. Participants could not be blinded; data extraction and statistical analyses were performed blinded to group assignment. The primary outcome was respiratory consultation rates.

Results We randomised 551 participants (274 intervention, 277 control) from whom the primary outcome was determined for 542 (269 intervention, 273 control). There was a 40% relative increase in respiratory consultations in the intervention group: (adjusted rates (95% CI) intervention 0.57 (0.47 to 0.70), control 0.41 (0.32 to 0.52), relative rate 1.40 (1.08 to 1.82); p=0.0123). There were no significant differences in time to first respiratory consultation, total consultation rates or measures of psychological harm. The incremental cost-effectiveness ratio was $A1289 per additional respiratory consultation.

Conclusions A behavioural intervention can significantly increase consulting for respiratory symptoms in patients at increased risk of lung cancer. This intervention could have an important role in primary care as part of a broader approach to improve respiratory health in patients at higher risk.

Trial registration number Australian New Zealand Clinical Trial Registry (1261300039 3752). This was registered pre-results.

INTRODUCTION

Lung cancer is the most common cancer worldwide and most common cause of cancer deaths.1 In Australia, there will be an estimated 12741 new cases and 9198 deaths due to lung cancer in 2018.2 Although there have been recent improvements in outcomes for lung cancer, 5-year survival in Australia is only 16%5 and less than 10% in the UK.3 This is primarily because most patients are diagnosed when curative surgical treatment is not possible.4

There is growing evidence that time to diagnosis in symptomatic patients is associated with clinical outcomes for lung cancer.5 Patient presentation to healthcare and initial management in primary care are key determinants of outcomes of patients with cancer.6 The Model of Pathways to Treatment describes symptom appraisal and help-seeking intervals as key timepoints along the cancer diagnostic pathway which contribute to overall time to diagnosis.7 Several studies have explored symptom appraisal and help-seeking in people recently diagnosed with lung cancer, identifying factors contributing to later presentation to healthcare. These include limited awareness of cancer symptoms, fear of cancer,8 concerns about wasting their own and general practitioners (GPs)’ time,9 stoicism10 and stigma around smoking.11 12 Current smokers are
more likely to experience respiratory symptoms but less likely to consult about them. Studies in rural Western Australia have found that normalisation of respiratory symptoms is common, especially in those with respiratory comorbidities, with median patient delays to seek help of 50–80 days. These times should be compared with lung cancer median volume doubling times of 98 days suggesting such delays could be clinically significant.

The US National Lung Cancer Screening Trial found a 20% relative reduction in lung cancer mortality from annual low-dose CT, but the limited cost-effectiveness and feasibility of implementing national lung cancer screening programmes means that other approaches to timely diagnosis of lung cancer are needed. The search for useful biomarkers of lung cancer shows promise, but is still at the validation stage. An alternative strategy is to attempt to diagnose lung cancer earlier through prompt recognition and investigation of symptoms suggestive of the disease, particularly in those at higher risk of lung cancer.

Mass media campaigns to raise symptom awareness have shown variable evidence of effect. Data from the ‘Be Clear on Cancer’ campaigns in England, have suggested potentially useful short-term effects including increased presentations to general practice and detection of earlier stage lung cancer, but these are based on comparisons with historical control data. A trial in rural Western Australia of a mass media campaign, which included lung cancer symptom awareness, failed to demonstrate an effect on time of presentation to healthcare or time to diagnosis.

Instead of mass media approaches, more targeted interventions could promote earlier presentation to healthcare in individuals at increased risk of lung cancer. The CHEST Trial in Scotland was the first to show preliminary evidence that this approach could alter overall consultation patterns in this population. In that trial, a theoretically based intervention delivered in primary care to patients at increased risk of lung cancer significantly increased the overall consultation rate by 15%; it was not powered to detect differences in respiratory consultations.

We have adapted the Scottish CHEST intervention for an Australian population. While maintaining its core theoretical elements, we modified the language and format of the self-help manual and expanded approaches to prompt symptom monitoring. We report the results of the CHEST Australia Trial which aimed to test the modified CHEST Intervention in an Australian primary care population and measure its effect on consultation rates for respiratory symptoms.

METHODS
As we have published the trial protocol, we report the methods here in brief.

Trial design
Individually randomised controlled trial conducted in 11 general practices in Perth, Western Australia, and 6 in Melbourne, Victoria, Australia.

Participants
Eligible participants were long-term smokers with at least 20 pack-years, aged 55 and above, including ex-smokers if their cessation date was less than 15 years ago. Participants were able to read and write English and give informed consent. Exclusion criteria included severe psychiatric or cognitive disorders or previous diagnosis of lung cancer.

Patients who potentially met eligibility criteria were identified from the general practice electronic medical record using the Canning data extraction software (www.canningtool.com.au). They were invited to participate in the study by letter from their general practice. Invitations included a patient information sheet and expression of interest form, which included four screening questions to assess smoking pack-years. Non-responders were followed up after 2 weeks with a reminder postcard. Eligible patients returning an expression of interest form were followed up by telephone to make a trial appointment at their general practice. Randomisation was performed after completion of baseline data and written informed consent had been obtained.

Intervention
A trained researcher performed spirometry and then guided the participant through a self-help manual, entitled Chest Symptoms that Call for Action. The key objectives of the manual were to: increase the salience and personal relevance of symptoms, improve knowledge of symptoms by introducing chest disease prototypes, reinforce the benefits of early intervention in lung cancer and other chest disease, and sanction early consultation. ‘If-then’ action plans were developed with the participant, linked to symptom checklists, and ‘If-then’ coping plans discussed to tackle barriers to consultation. A range of monthly prompts to monitor current symptoms were tailored to individual preferences, including SMS and email reminders, postcards, phone calls and fridge magnets.

Control
A trained researcher performed spirometry and then had a brief general discussion about lung health. This was designed as an attention control and to increase overall engagement in the trial for control participants. Participants then received usual care at their general practice.

In both trial groups, the results of the spirometry were sent to the participant’s GP for follow-up according to usual practice.

Outcomes and measures
The primary outcome of this trial was consultation rates for respiratory symptoms. Data on consultations in the year before the trial and for 12 months after the consultation were collected through audit of GP records. This was a phase II trial of a complex intervention; our outcomes were designed to test whether the intervention has the potential to facilitate the early detection of lung cancer by evaluating its effect across a range of intermediate endpoints.

Additional measures included
1. Demographics and clinical variables: age, gender, marital status, postcode, highest education level, occupation, Medical Research Council (MRC) Dyspnoea Scale and lung function at baseline only.
2. Self-efficacy for consulting without delay: a 10-item self-completed scale summed to score 10–100.
3. Knowledge of symptoms of lung disease: a 21-item self-completed checklist of possible symptoms expressed as a percentage correctly selected as associated with chest disease.
4. Symptom appraisal and help-seeking intervals measured using the SYMPTOM instrument (lung cancer version), a self-completed questionnaire that obtains data on presenting symptoms and their duration prior to consultation. Monthly electronic searches of the GP medical records identified recent respiratory consultations. Participants were sent a SYMPTOM questionnaire to complete about symptoms relating to that consultation.
5. Hospital Anxiety and Depression Scale (HADS). 31
6. Cancer-worry scale: a 6-item self-completed scale, adapted from the breast cancer worry scale and validated in the Scottish CHEST Trial. 25, 32
7. Quality of life using the Assessment of Quality of Life (AQoL-8D). 33
8. Health service utilisation: in addition to the primary measure of consultation rates for respiratory symptoms, total general practice consultation rates, chest X-ray requests and referrals to respiratory physicians were captured through audit of general practice medical records. Participants consented to access to their Medicare claims data (Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS)) obtained from the Department of Human Services. Medicare is the publicly funded universal healthcare system in Australia. Claims data provided more complete information about visits to other general practices, including prescribing, investigations and referrals arising from these. Participant-completed measures were collected at baseline, 1 and 12 months, with the exception of the SYMPTOM

Figure 1  Trial flow chart. GP, general practitioner.
instrument as already described. Health service utilisation data were collected at 12 months from an audit of general practice medical records and obtaining Medicare claims data.

**Sample size**

Data from the Scottish trial was used to inform power calculations. Assuming that the primary endpoint of consultations for respiratory symptoms follows a Poisson distribution, and that the expected average rate over 12 months in the study population would be 1.06 for control patients and 25% higher for intervention patients, a sample of 534 would provide at least 80% power to reject the null hypothesis of no difference between the groups at the two-sided 5% level of significance. Accounting for the same attrition rate observed in the Scottish CHEST trial, we required a total sample of 550 participants.

**Randomisation**

Those who met the eligibility criteria and who consented to participate were randomised 1:1 to either the control or intervention. Randomisation was performed using a centralised independent telerandomisation system managed by the National Health and Medical Research Council (NHMRC) Clinical Trials

| Characteristic | Level | Intervention (N=274) | Control (N=277) |
|----------------|-------|----------------------|----------------|
| Age: mean (SD) (n) | 64.38 (9.8) (274) | 64.07 (10.64) (277) |
| Sex | Female | 117 (42.7%) | 114 (41.2%) |
| | Male | 157 (57.3%) | 163 (58.8%) |
| FEV1: mean (SD) (n) | 80.90 (21.65) (273) | 81.63 (20.51) (276) |
| Smoking pack-years: mean (SD) (n) | 45.18 (23.84) (274) | 45.99 (24.4) (277) |
| Smoking status | Ex-smoker | 168 (61.3%) | 148 (53.4%) |
| | Current | 106 (38.7%) | 129 (46.6%) |
| Comorbidities | Cardiovascular | 100 (36.5%) | 115 (41.5%) |
| | Respiratory | 90 (32.8%) | 89 (32.1%) |
| | Psychiatric | 44 (16.1%) | 41 (14.8%) |
| | Diabetes | 28 (10.2%) | 35 (12.6%) |
| | Other | 92 (33.6%) | 92 (33.2%) |
| Respiratory consultations from 12 months to baseline: mean (SD) (n) | 0.86 (1.62) (269) | 0.76 (1.25) (273) |
| All consultations from 12 months to baseline: mean (SD) (n) | 9.06 (7.49) (270) | 9.11 (7.70) (273) |
| Accommodation | Own your home | 204 (74.5%) | 212 (76.5%) |
| | Rent your home | 50 (18.2%) | 33 (11.9%) |
| | Other (please specify below) | 20 (7.3%) | 22 (7.9%) |
| | Missing | 0 | 10 (3.6%) |
| Education | Year 11 or below | 86 (31.4%) | 89 (32.1%) |
| | Year 12 or equivalent | 40 (14.6%) | 38 (13.7%) |
| | Trade/apprenticeship | 29 (10.6%) | 39 (14.1%) |
| | Tertiary certificate/diploma | 49 (17.9%) | 57 (20.6%) |
| | Undergraduate university degree | 24 (8.8%) | 17 (6.1%) |
| | Postgraduate university degree | 17 (6.2%) | 12 (4.3%) |
| | Other (please specify) | 26 (9.5%) | 17 (6.1%) |
| | Missing | 3 (1.1%) | 8 (2.9%) |
| Living arrangements | On your own | 70 (25.5%) | 70 (25.3%) |
| | With a partner/spouse | 166 (60.6%) | 166 (59.9%) |
| | With other family | 32 (11.7%) | 28 (10.1%) |
| | Other (please specify below) | 6 (2.2%) | 5 (1.8%) |
| | Missing | 0 | 8 (2.9%) |
| Occupation (more than one can apply) | Retired | 85 (31.0%) | 98 (35.4%) |
| | Caring for dependent relative | 14 (5.1%) | 16 (5.8%) |
| | Voluntary worker | 20 (7.3%) | 14 (5.1%) |
| | Unemployed | 52 (19.0%) | 63 (22.7%) |
| | Student | 8 (2.9%) | 3 (1.1%) |
| | Looking after home/family | 43 (15.7%) | 48 (17.3%) |
| | Disabled/unable to work | 21 (7.7%) | 22 (7.9%) |

---

Emery JD, et al. Thorax 2019;0:1–9. doi:10.1136/thoraxjnl-2018-212506
Centre, based at the University of Sydney. Stratifying variables for randomisation were MRC dyspnoea score (scores 1–3 and 4–5) and general practice recruitment site.

**Blinding**

Outcomes assessed by self-report obviated the need for researcher blinding. For the extraction and analysis of health service utilisation data, research staff were blinded to group assignment. All statistical analyses were performed blinded to group assignment.

**Statistical methods**

All randomised patients were considered eligible for inclusion in the analysis in accordance with the intention-to-treat analysis principle. In accordance with the provision specified in the statistical analysis plan, a negative binomial model was used for the analysis of data on consultation rates because of overdispersion that rendered the Poisson model inappropriate. The model included general practice as a fixed effect and accounted for additional variation due to repeat consultations by the same participant. The effect of clustering arising from couples being randomised together was explored by fitting the model using the method of generalised estimating equations. Comparisons between groups on categorical secondary endpoints were performed using a linear model that included general practice fitted as a factor and the baseline value as a covariate (where applicable). Comparisons between groups on categorical secondary endpoints were repeated adjusting for additional variation due to repeat consultations by the same participant. The analyses performed on the primary endpoints were performed using logistic regression with general practice fitted as a factor. The analyses performed on the primary endpoints were performed using logistic regression with general practice fitted as a factor and the baseline value as a covariate (where applicable). Comparisons between groups on categorical secondary endpoints were performed using logistic regression sets were used to compare randomised groups on time to first consultation for a respiratory symptom from baseline.

Costs of delivering the CHEST intervention were calculated to include: identification of the at-risk population, invitation processes, training to deliver the CHEST intervention, consultation time (assuming delivered by a practice nurse), spirometry equipment including laptop computer, and patient reminders. Total health service costs were derived by multiplying the resource used by the relevant MBS and PBS fee; these data included patient copayment contribution. Costs are reported as undiscounted cost for 2016. We calculated an incremental cost-effectiveness ratio (ICER) per additional respiratory consultation. We performed sensitivity analyses including the costs of spirometry equipment as this was not a core part of the intervention.

**RESULTS**

Between 29 May 2013 and 19 November 2015, we approached 2501 current and 2666 ex-smokers, and 112 with unclear quit status; 940 of these (17.8%) responded. Of these, 623 (66%) met our eligibility criteria and 551 (88%) consented to be randomised (see figure 1).

Table 1 presents baseline data on the trial cohort. Patients who did not respond to the initial trial invitation were similar in terms of age (mean 65.7 years) and sex (56.0% male) but were more likely to be current smokers (48.0% vs 42.6%). There was a higher proportion of current smokers in the control than intervention group (46.6% vs 38.7%) but no other between-group imbalances. Three patients were diagnosed with lung cancer during the 12-month follow-up, two in the intervention group and one in the control group.

The primary outcome was determined for 542 participants (98.3%); 12-month questionnaire data were available on 416 participants (intervention 212 (77%); control 204 (74%)). SYMPTOM questionnaires were completed for 88% of intervention and 66% of control consultations.

Table 2 presents data on total GP consultations and those for respiratory symptoms. On average, the overall cohort consulted their GP approximately nine times over the 12-month follow-up regression) were used to compare randomised groups on time to first consultation for a respiratory symptom from baseline.

Table 3 presents data on total GP consultations and those for respiratory symptoms. On average, the overall cohort consulted their GP approximately nine times over the 12-month follow-up
Lung cancer

period, but the majority did not consult at all about respiratory symptoms (intervention 59.5% vs control 66.4%). In the negative binomial model, with trial group and practice site as covariates, there was a 40% relative increase in respiratory consultations in the intervention group: (adjusted rates (95% CI) intervention 0.57 (0.47 to 0.70), control 0.41 (0.32 to 0.52), relative rate 1.40 (1.08 to 1.82); p=0.0123). This effect remained after adjusting for additional baseline covariates (table 3).

In the negative binomial model, with trial group and practice site as covariates, there was no difference between groups on total consultation rates: (adjusted rates (95% CI), intervention 8.52 (7.63 to 9.52), control 8.45 (7.51 to 9.50), relative rate 1.01 (0.88 to 1.16); p=0.8998).

Table 4 presents the results of mixed model repeated measures analyses of HADS, cancer worry and AQoL-8D data. There were no statistically significant differences between trial groups in depression, general or cancer-specific anxiety, or quality of life. Table 5 shows that there were no significant differences between trial groups over time in perceived risk, self-efficacy to consult or knowledge of symptoms lung disease.

Table 6 presents the results on time from onset of respiratory symptom to GP consultation, for all consultations combined and for each serial consultation. Figure 2 presents the survival analysis curves for time to first respiratory consultation. In the survival analyses, there was no significant difference in time to first respiratory consultation (log-rank test: $\chi^2$ 1.5923 (degrees of freedom (df) 1), p>$\chi^2$ 0.207) or time to present for all consultations (HR 0.827; 95% CI 0.64 to 1.07; p=0.147).

There were 46 chest X-rays ordered in the intervention group (mean 0.24 per person) and 50 in the control group (mean 0.25 per person). We were unable to identify accurately all referrals to respiratory specialists. The cost of the CHEST intervention (base case) was $A207.77 (SD $A99.22) per participant in the intervention group. Based on the adjusted respiratory consultation rate at 12 months, this equates to an ICER per additional respiratory consultation of $A1289. In the sensitivity analysis, including the costs of spirometry equipment, the CHEST intervention cost $A816.91 (SD $A606.75) per participant in the intervention group, with an ICER of $A5105 per additional respiratory consultation.

**DISCUSSION**

**Summary**

This is the largest trial yet to test the effect of a behavioural intervention to promote help-seeking in patients at increased risk of lung cancer. We demonstrated a statistically significant 40% relative increase in consultations about respiratory symptoms

---

Table 4: HADS, cancer worry and AQoL-8D over time and between groups

| Month | Randomised group | N  | Mean | SD  | Min | Max | LS mean | LS Mean difference | Lower 95% CI | Upper 95% CI | P-value for difference | P-value for difference rank analysis |
|-------|------------------|----|------|-----|-----|-----|--------|-------------------|-------------|-------------|------------------------|-------------------------------------|
| Anxiety |                      |    |      |     |     |     |        |                   |             |             |                        |                                    |
| 0     | Control          | 268| 5.6  | 4.1 | 0.0 | 21.0|        |                   |             |             |                        |                                    |
| 0     | Intervention     | 269| 5.7  | 3.9 | 0.0 | 21.0|        |                   |             |             |                        |                                    |
| 1     | Control          | 223| 5.3  | 4.2 | 0.0 | 18.0| 5.5    |                   |             |             |                        |                                    |
| 1     | Intervention     | 234| 5.3  | 4.0 | 0.0 | 20.0| 5.3    | $-0.2$            | $-0.7$      | 0.3          | 0.3954                 | 0.6054                              |
| 12    | Control          | 204| 5.2  | 4.2 | 0.0 | 18.0| 5.6    |                   |             |             |                        |                                    |
| 12    | Intervention     | 212| 5.3  | 4.1 | 0.0 | 19.0| 5.4    | $-0.1$            | $-0.6$      | 0.4          | 0.6083                 | 0.5179                              |
| Depression |                  |    |      |     |     |     |        |                   |             |             |                        |                                    |
| 0     | Control          | 268| 4.4  | 3.8 | 0.0 | 20.0|        |                   |             |             |                        |                                    |
| 0     | Intervention     | 269| 4.1  | 3.4 | 0.0 | 19.0|        |                   |             |             |                        |                                    |
| 1     | Control          | 223| 4.3  | 4.1 | 0.0 | 21.0| 4.2    |                   |             |             |                        |                                    |
| 1     | Intervention     | 234| 3.9  | 3.5 | 0.0 | 16.0| 3.9    | $-0.3$            | $-0.7$      | 0.1          | 0.1557                 | 0.1218                              |
| 12    | Control          | 204| 4.4  | 4.1 | 0.0 | 21.0| 4.2    |                   |             |             |                        |                                    |
| 12    | Intervention     | 212| 3.9  | 3.5 | 0.0 | 19.0| 4.0    | $-0.2$            | $-0.7$      | 0.2          | 0.3672                 | 0.3344                              |
| Cancer worry |               |    |      |     |     |     |        |                   |             |             |                        |                                    |
| 0     | Control          | 268| 3.4  | 3.2 | 0.0 | 17.0|        |                   |             |             |                        |                                    |
| 0     | Intervention     | 269| 3.4  | 3.2 | 0.0 | 17.0|        |                   |             |             |                        |                                    |
| 1     | Control          | 223| 3.3  | 3.3 | 0.0 | 16.0| 3.7    |                   |             |             |                        |                                    |
| 1     | Intervention     | 234| 3.2  | 3.1 | 0.0 | 18.0| 3.5    | $-0.2$            | $-0.7$      | 0.2          | 0.3381                 | 0.4166                              |
| 12    | Control          | 204| 2.9  | 3.0 | 0.0 | 16.0| 3.5    |                   |             |             |                        |                                    |
| 12    | Intervention     | 212| 2.8  | 3.2 | 0.0 | 18.0| 3.2    | $-0.3$            | $-0.7$      | 0.2          | 0.2436                 | 0.1576                              |
| Quality of life |                 |    |      |     |     |     |        |                   |             |             |                        |                                    |
| 0     | Control          | 268| 76.5 | 13.6| 23.4| 124.8|        |                   |             |             |                        |                                    |
| 0     | Intervention     | 268| 77.1 | 12.2| 27.7| 115.6|        |                   |             |             |                        |                                    |
| 1     | Control          | 221| 77.5 | 15.9| 11.4| 124.8| 78.1    |                   |             |             |                        |                                    |
| 1     | Intervention     | 234| 79.6 | 14.2| 31.2| 124.8| 79.3    | 1.2               | $-0.9$      | 3.2          | 0.2562                 | 0.1915                              |
| 12    | Control          | 203| 77.2 | 14.5| 20.6| 124.8| 78.1    |                   |             |             |                        |                                    |
| 12    | Intervention     | 213| 79.1 | 15.1| 27.0| 124.8| 78.8    | 0.7              | $-1.4$       | 2.8          | 0.5111                 | 0.5923                              |

AQoL, Assessment of Quality of Life; CL, confidence limit; HADS, Hospital Anxiety and Depression Scale; LS, least square; Max, maximum; Min, minimum.
Lung cancer in those receiving the intervention but no overall increase in consultation rates. There was a non-significant mean reduction of 14 days in time to first presentation with respiratory symptoms. There was no evidence of psychological harm from the intervention.

Limitations
This was designed as a phase II efficacy trial of a complex intervention. The primary outcome of respiratory consultation rates is based on the intervention logic model: by encouraging patients at increased risk of lung cancer to consult their GP when they develop respiratory symptoms, this would reduce the diagnostic delay of lung cancer and potentially result in the detection of earlier stage disease. Our primary outcome is, therefore, a suitable intermediate measure along this causal pathway. However, even in this population at increased risk of lung cancer, during a 12-month follow-up period, only three participants (0.54%) were diagnosed with lung cancer. It would require a substantially larger trial to be powered even to detect differences in time to diagnosis of lung cancer, let alone in clinical outcomes such as lung cancer stage or mortality. The control group received spirometry and a brief discussion about lung health. This was intended as an attention control but could potentially have also increased consultation rates for respiratory symptoms. There was also a chance imbalance between groups, with a higher proportion of current smokers in the control group. Both of these limitations could have reduced the estimated effect size of the CHEST intervention. We achieved a very low attrition rate for the primary outcome (98.3%), but we had greater loss-to-follow-up for the

### Table 5 Perceived risk, self-efficacy and knowledge scores over time and between group

| Month | Randomised group | N   | Mean  | SD    | Min | Max | LS mean | LS mean difference | Lower 95% CL | Upper 95% CL | P-value for difference rank analysis |
|-------|------------------|-----|-------|-------|-----|-----|---------|-------------------|-------------|-------------|-------------------------------------|
|       |                  |     |       |       |     |     |         |                   |             |             |                                     |
|       | Control          | 268 | 6.9   | 1.9   | 0.0 | 10.0| 6.9     |                   |             |             |                                     |
| 0     | Intervention     | 269 | 6.9   | 1.7   | 0.0 | 10.0| 6.9     |                   |             |             |                                     |
| 1     | Control          | 223 | 6.7   | 2.0   | 0.0 | 10.0| 6.7     |                   |             |             | 0.2 (−0.0, 0.5) 0.0728 0.0836     |
| 1     | Intervention     | 234 | 7.0   | 1.7   | 2.0 | 10.0| 7.1     | 0.2               | −0.0         | 0.5          |                                     |
| 12    | Control          | 204 | 6.7   | 1.9   | 0.0 | 10.0| 6.7     |                   |             |             | 0.1 (−0.2, 0.3) 0.6452 0.4904     |
| 12    | Intervention     | 212 | 6.7   | 1.9   | 0.0 | 10.0| 6.7     |                   |             |             |                                     |

**Perceived risk**
- 0 Control: 6.9, SD 1.9, mean 6.9
- 0 Intervention: 6.9, SD 1.7, mean 6.9
- 1 Control: 6.7, SD 2.0, mean 6.7
- 1 Intervention: 7.0, SD 1.7, mean 7.1
- 12 Control: 6.7, SD 1.9, mean 6.7
- 12 Intervention: 6.7, SD 1.9, mean 6.7

**Self-efficacy**
- 0 Control: 85.0, SD 24.2, mean 85.0
- 0 Intervention: 87.3, SD 24.6, mean 87.3
- 1 Control: 89.1, SD 21.7, mean 89.1
- 1 Intervention: 92.4, SD 19.6, mean 92.4
- 12 Control: 90.7, SD 20.0, mean 90.7
- 12 Intervention: 94.5, SD 17.5, mean 94.5

**Knowledge**
- 0 Control: 9.0, SD 5.4, mean 9.0
- 0 Intervention: 8.7, SD 5.9, mean 8.7
- 1 Control: 9.4, SD 5.4, mean 9.4
- 1 Intervention: 9.4, SD 6.2, mean 9.4
- 12 Control: 8.8, SD 5.9, mean 8.8
- 12 Intervention: 9.7, SD 6.1, mean 9.7

CL, confidence limit; LS, least square; Max, maximum; Min, minimum.

### Table 6 Time from symptom onset to consultation

| Characteristic | Intervention (N=274) | Control (N=277) |
|---------------|----------------------|-----------------|
| All consultations: mean days (SD) (n) | 66.9 (109.18) (107) | 76.32 (102.31) (94) |
| Median days (min–max) | 21 (1–365) | 30 (2–365) |
| Appointment 1: mean (SD) (n) | 62.5 (102.26) (76) | 76.29 (102.52) (70) |
| Median days (min–max) | 21 (2–365) | 30 (2–365) |
| Appointment 2: mean (SD) (n) | 71.22 (119.75) (23) | 83.85 (111.74) (20) |
| Median days (min–max) | 14 (3–365) | 30 (2–365) |
| Appointment 3: Mean (SD) (n) | 68 (132.63) (7) | 39.25 (37.85) (4) |
| Median days (min–max) | 7 (1–365) | 30 (7–90) |
| Appointment 4: mean (SD) (n) | 304 (304–304) | - |
| Median days (min–max) | 304 (304–304) | - |

CL, confidence limit; LS, least square; Max, maximum; Min, minimum.

**Figure 2** Survival curve for time from symptom onset to first consultation.

Emery JD, et al. Thorax 2019;0:1–9. doi:10.1136/thoraxjnl-2018-212506

on March 19, 2020 by guest. Protected by copyright.
patient-reported outcomes. In particular, there was greater attrition for responses to the SYMPTOM questionnaire in the control group. This might have biased our estimates of the effect of the intervention on time to GP consultation but it is difficult to know in which direction.

**Generalisability**

We recruited patients from general practices in two large Australian cities and from suburbs with a range of socioeconomic deprivation. Patients at increased risk of lung cancer are a ‘hard-to-reach’ group due to smoking stigma and socioeconomic deprivation. The response rate to the mailed invitation into the trial was 18% of whom only 66% were eligible. Our final accrual rate was 10.6%; while participants had a similar age and sex distribution to non-responders, there was a higher proportion of ex-smokers in the trial (60% vs 51% in the invited population). It is possible that there was a selection bias towards those with less severe respiratory disease given the low rate of baseline respiratory consultations and lung function results. It is difficult to know in which direction this bias might affect our estimate of the effect size of the CHEST intervention. Current smokers may have greater barriers to consulting and therefore we might have seen a larger effect size in a less biased sample. Alternatively, those with more severe respiratory disease may be more frequent consulters at baseline, thereby reducing any potential effect on consultation rates.

**Interpretation**

Previous research in England found that patients at increased risk of lung cancer commonly have symptoms associated with lung cancer but many do not seek help about these symptoms. Smokers in particular are less likely than non-smokers to consult their GP when they develop respiratory symptoms. Non-consulters have higher tolerance for their symptoms, are more likely to self-manage and have greater concern about wasting their GP’s time. Qualitative research with GPs has questioned the value of mass media symptom awareness campaigns due to concerns about overwhelming the health system. Together, these findings have led to calls for targeted interventions in primary care to improve symptom recognition and empower help-seeking in patients at increased risk of lung cancer.

Our parallel qualitative evaluation of the CHEST trial confirmed the theoretical underpinning of the intervention: we found evidence of reduction in stigma and guilt, increase in salience and personal relevance of symptoms and sanctioning of help-seeking, which translated into increased respiratory consultations. Of interest, in the trial we found no difference in our quantitative measures of knowledge, self-efficacy to consult, risk perception or measures of general and cancer-specific anxiety. We measured anxiety as a potential harm of the intervention. The theoretical models underpinning the CHEST intervention did not suggest we needed to create anxiety to have an effect; indeed, fear of cancer can be a barrier to help-seeking. The CHEST intervention did not alter overall consultation rates but had a specific effect on help-seeking for respiratory symptoms. Although it prompted more respiratory consultations, there was only a small reduction in the duration of symptoms before seeking help; an average of 14 days earlier for the first consultation and 9 days for all respiratory consultations. Participants in the intervention group took an average of 2 months from symptom onset to consult about a new respiratory symptom. This size of effect is unlikely to be of clinical significance. The intervention made it more likely that someone would present with respiratory symptoms, but further consideration is required on how to prompt even earlier presentation with these symptoms. It may be that additional interventions aimed at the GP are required. Patients with lung cancer often have multiple GP visits about respiratory symptoms before referral to a specialist for definitive diagnosis. By highlighting that these patients are at increased risk of lung cancer, they could potentially be investigated sooner by their GP and reduce the overall diagnostic interval.

The CHEST intervention cost $A1289 per additional respiratory consultation. In the absence of trial data with sufficient numbers of lung cancer cases, it is difficult to estimate the cost per lung case detected. If we assume that 3% of these consultations led to a diagnosis of lung cancer, this would equate to approximately $A42.500 per case detected.

Significant uncertainty therefore remains about the best strategies to promote earlier detection of lung cancer. The US Preventive Services Taskforce has recommended low-dose CT screening for adults aged 55 to 80 years with at least a 30 pack-year smoking history. Other countries are still considering the evidence to inform national policy. In Australia, the cost-effectiveness of lung cancer CT screening is estimated at $A2.33000 per quality-adjusted life-year gained, making it less likely to be implemented in the near future. Together, these findings have led to calls for targeted interventions in primary care to improve symptom recognition and empower help-seeking in patients at increased risk of lung cancer.

A key implementation challenge for CT screening is the identification of the screening population. The findings of the CHEST Australia trial should perhaps be considered in the broader context of respiratory disease management in primary care including lung cancer and COPD. International guidelines currently do not recommend screening for COPD, but instead suggest a case-finding approach in patients at risk of the condition who have respiratory symptoms. The CHEST intervention could therefore be a way to identify patients at increased risk of either lung cancer or COPD and include spirometry as part of a respiratory health consultation. In those at very high risk of lung cancer (eg, more than 30 pack-years smoking history), low-dose CT screening would be recommended in some countries. For those at moderate risk of lung cancer, the behavioural CHEST intervention could raise patient awareness of respiratory symptoms, reduce stigma and promote help-seeking. This could potentially improve the management of COPD and prompt earlier assessment by their GP for lung cancer. The CHEST intervention is a relatively low-cost option which might have broader implications for improving the management of respiratory symptoms, and serious lung disease, in primary care.

**Author affiliations**

1Department of General Practice and Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia
2Department of General Practice, The Medical School, University of Western Australia, Perth, Australia
3The Primary Care Unit, Public Health and Primary Care, University of Cambridge, Cambridge, UK
4NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
5Centre for Health Economics Research and Evaluation, University of Technology Sydney

Emery JD, et al. Thorax 2019;0:1–9. doi:10.1136/thoraxjnl-2018-212506
Lung cancer

Emery JD, Gray WA, Woodcock M, Solomon AM, Hunt K, Barrie SE, et al. The improving rural cancer outcomes (IRCOn) trial: a cluster-randomised controlled trial of an internet-based intervention to reduce time to diagnosis in rural cancer patients in Western Australia. Br J Cancer 2017;117:1459-69.

Contributions: We thank all the trial participants and general practitioners who were involved in the trial. The Centre of Academic Primary Care, University of Sheffield, Alberts, UK.

Funding: This trial was funded by the NRHM (grant ID 16412). It was supported by a Clinician Scientists award (R8/GR235) from the National Institute for Health Research. All authors contributed to the drafting of the manuscript and approved the final version. JD Emery, Walter FM, Solomon AM, Hunt K, Barrie SE, et al. The improving rural cancer outcomes (IRCOn) trial: a cluster-randomised controlled trial of an internet-based intervention to reduce time to diagnosis in rural cancer patients in Western Australia. Br J Cancer 2017;117:1459-69.

Competing interests: None declared.

Patient consent for publication: No required.

Ethics approval: University of Western Australia Human Research Ethics Committee (with reference number 14413).

Provenance and peer review: Not commissioned; externally peer reviewed.

REFERENCES

1. International Agency for Research on Cancer. Lung cancer estimated incidence, mortality and prevalence worldwide 2017. International Agency for Research on Cancer, 2018.

2. Cancer Australia. Lung cancer in Australia. Sydney: Cancer Australia, 2018.

3. Australian Cancer Database 2017. Grounds M, et al. Cancer Incidence in Australia: Australian Institute of Health and Welfare 2018, Canberra.

4. Johnston AL, McKee DE, McLaughlin JK, De Angelis P. Trends in lung cancer mortality in England and Wales: relative and attributable risks in relation to smoking. Br J Cancer 2002;86:108-14.

5. Johnston AL, McKee DE, McLaughlin JK, De Angelis P. Trends in lung cancer mortality in England and Wales: relative and attributable risks in relation to smoking. Br J Cancer 2002;86:108-14.

6. Neal RD, Thrushman H, Farnon B, et al. Lung cancer in England: the Lung Cancer Patient Experience Survey. 2014. 2015;162:96-100.

7. Neal RD, Thrushman H, Farnon B, et al. Lung cancer in England: the Lung Cancer Patient Experience Survey. 2014. 2015;162:96-100.

8. Neal RD, Thrushman H, Farnon B, et al. Lung cancer in England: the Lung Cancer Patient Experience Survey. 2014. 2015;162:96-100.

9. Neal RD, Thrushman H, Farnon B, et al. Lung cancer in England: the Lung Cancer Patient Experience Survey. 2014. 2015;162:96-100.

10. Neal RD, Thrushman H, Farnon B, et al. Lung cancer in England: the Lung Cancer Patient Experience Survey. 2014. 2015;162:96-100.